SZSE:300194 (China)
Â
Class A
Â¥
4.41
+0.13 (+3.04%)
Mar 14
What is a stock summary page? Click here for an overview.
Business Description
Fuan Pharmaceutical (Group) Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE1000011G4
Share Class Description:
SZSE:300194: Class ACompare
Compare
Traded in other countries / regions
300194.China IPO Date
2011-03-22Description
Fuan Pharmaceutical (Group) Co Ltd is mainly engaged in the production and sales of bulk drugs and preparations. The company mainly deals with anti-infective, anti-tumor, mental nervous system, cardiovascular and cerebrovascular, digestive system, endocrine and metabolic, bone and muscle systems. Its products include penicillin and cephalosporins.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.36 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | 1.86 | |||||
| Interest Coverage | 11.72 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.88 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.1 | |||||
| 3-Year EBITDA Growth Rate | 7.4 | |||||
| 3-Year EPS without NRI Growth Rate | -60.3 | |||||
| 3-Year Book Growth Rate | 0.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 213.45 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 8.09 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.56 | |||||
| 9-Day RSI | 60.56 | |||||
| 14-Day RSI | 54.67 | |||||
| 3-1 Month Momentum % | -10.02 | |||||
| 6-1 Month Momentum % | 19.73 | |||||
| 12-1 Month Momentum % | 20.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.66 | |||||
| Quick Ratio | 1.06 | |||||
| Cash Ratio | 0.74 | |||||
| Days Inventory | 206.45 | |||||
| Days Sales Outstanding | 37.2 | |||||
| Days Payable | 116.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.17 | |||||
| Dividend Payout Ratio | 0.21 | |||||
| Forward Dividend Yield % | 1.17 | |||||
| 5-Year Yield-on-Cost % | 1.16 | |||||
| Shareholder Yield % | 5.28 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.33 | |||||
| Operating Margin % | 11.48 | |||||
| Net Margin % | 10.59 | |||||
| FCF Margin % | 8.24 | |||||
| ROE % | 6.61 | |||||
| ROA % | 4.66 | |||||
| ROIC % | 5.37 | |||||
| 3-Year ROIIC % | -10.83 | |||||
| ROC (Joel Greenblatt) % | 19.16 | |||||
| ROCE % | 7.97 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.17 | |||||
| Forward PE Ratio | 11.6 | |||||
| PE Ratio without NRI | 18.15 | |||||
| Shiller PE Ratio | 40.09 | |||||
| Price-to-Owner-Earnings | 441 | |||||
| PS Ratio | 2.05 | |||||
| PB Ratio | 1.19 | |||||
| Price-to-Tangible-Book | 1.46 | |||||
| Price-to-Free-Cash-Flow | 24.89 | |||||
| Price-to-Operating-Cash-Flow | 11.73 | |||||
| EV-to-EBIT | 12.65 | |||||
| EV-to-EBITDA | 12.65 | |||||
| EV-to-Revenue | 1.82 | |||||
| EV-to-FCF | 21.9 | |||||
| Price-to-GF-Value | 0.98 | |||||
| Price-to-Projected-FCF | 1.54 | |||||
| Price-to-Median-PS-Value | 0.86 | |||||
| Price-to-Graham-Number | 1.09 | |||||
| Price-to-Net-Current-Asset-Value | 10.02 | |||||
| Earnings Yield (Greenblatt) % | 7.91 | |||||
| FCF Yield % | 4.18 | |||||
| Forward Rate of Return (Yacktman) % | 22.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fuan Pharmaceutical (Group) Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 2,660.049 | ||
| EPS (TTM) (Â¥) | 0.23 | ||
| Beta | 0.94 | ||
| 3-Year Sharpe Ratio | 0.03 | ||
| 3-Year Sortino Ratio | 0.04 | ||
| Volatility % | 28.28 | ||
| 14-Day RSI | 54.67 | ||
| 14-Day ATR (Â¥) | 0.090164 | ||
| 20-Day SMA (Â¥) | 4.3285 | ||
| 12-1 Month Momentum % | 20.7 | ||
| 52-Week Range (Â¥) | 3.41 - 5.68 | ||
| Shares Outstanding (Mil) | 1,189.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fuan Pharmaceutical (Group) Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fuan Pharmaceutical (Group) Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Fuan Pharmaceutical (Group) Co Ltd Frequently Asked Questions
What is Fuan Pharmaceutical (Group) Co Ltd(SZSE:300194)'s stock price today?
The current price of SZSE:300194 is ¥4.41. The 52 week high of SZSE:300194 is ¥5.68 and 52 week low is ¥3.41.
When is next earnings date of Fuan Pharmaceutical (Group) Co Ltd(SZSE:300194)?
The next earnings date of Fuan Pharmaceutical (Group) Co Ltd(SZSE:300194) is .
Does Fuan Pharmaceutical (Group) Co Ltd(SZSE:300194) pay dividends? If so, how much?
The Dividend Yield %  of Fuan Pharmaceutical (Group) Co Ltd(SZSE:300194) is 1.17% (As of Today), Highest Dividend Payout Ratio of Fuan Pharmaceutical (Group) Co Ltd(SZSE:300194) was 5. The lowest was 0.15. And the median was 0.39. The  Forward Dividend Yield % of Fuan Pharmaceutical (Group) Co Ltd(SZSE:300194) is 1.17%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers